Should You Continue to Retain QIAGEN Stock in Your Portfolio Now?
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
Here's Why Qiagen (QGEN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
QGEN Stock to Gain From Expanding QIAstat-Dx With New Barcelona Site
QIAGEN's new Barcelona site is set to drive QIAstat-Dx's growth in infectious diseases and precision medicine testing.
QGEN Stock Dips Despite Launch of Customized dPCR Assay Design Tools
QIAGEN introduces two new customizable dPCR assay design tools featuring advanced design algorithms tailored for diverse microbial applications and custom NGS panels.
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Innovations Support QIAGEN Shares Despite Macroeconomic Concerns
To support internal growth, QGEN heavily invests in R&D for the menu expansion of its key platforms.
Reasons to Retain QIAGEN Stock in Your Portfolio for Now
Investors feel optimistic about QGEN's growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is concerning.
QGEN Collaborates With McGill University Centre: Stock to Gain?
QIAGEN joins forces with McGill University Centre for Microbiome Research to generate evidence-based knowledge for medicine and public health.
Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Qiagen N.V. (QGEN) Q3 2024 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN ) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ET Company Participants John Gilardi - VP, Head of Corporate Communications and IR Thierry Bernard - CEO Roland Sackers - CFO Conference Call Participants Patrick Donnelly - Citi Odysseas Manesiotis - Berenberg Matt Sykes - Goldman Sachs Doug Schenkel - Wolfe Research Aisyah Noor - Morgan Stanley Michael Ryskin - Bank of America Casey Woodring - JP Morgan Andrew Brackmann - William Blair Operator Ladies and gentlemen, thank you for standing by.
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up
QGEN delivers another solid performance in the third quarter of 2024, with both the top and bottom lines surpassing estimates.
